



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Lenacapavir Gilead

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	This was an application for a group of	19/02/2026		SmPC,	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000323127

variations.

B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack -
B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted
B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted

Labelling and PL